$
0.69
Change
+0.01 +1.47%
Volume
Volume 35,207
May 18, 2022, 1:07 p.m.
Quotes are delayed by 15 min
Previous close
$ 0.68
$ 0.69
Change
+0.01 +1.47%
Day low
Day high
$0.66
$0.69

52 week low
52 week high
$0.64
$4.22

Market cap
$35.27M
Average volume
27,096
P/E ratio
N/A
Rev. per Employee
$210,259
EPS
-0.53
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on ATE
No News currently available for ATE
Other News on ATE
Press Releases on ATE
-
Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary
- BusinessWire - BZX
-
Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results
- BusinessWire - BZX
-
Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results
- BusinessWire - BZX
-
Antibe Therapeutics Outlines Plan for Otenaproxesul's Acute Pain Program
- BusinessWire - BZX
-
Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline
- BusinessWire - BZX
-
Antibe Therapeutics Announces Results of 2021 Annual Meeting
- BusinessWire - BZX
-
Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results
- BusinessWire - BZX
-
Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
- BusinessWire - BZX
-
Antibe Therapeutics Provides Clinical Update for Otenaproxesul
- BusinessWire - BZX
-
Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights
- BusinessWire - BZX
-
This Could Massively Disrupt the $24.35 Billion NSAID Market
- Baystreet.ca
-
Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences
- BusinessWire - BZX
-
InvestorNewsBreaks - Universal Ibogaine Inc. Appoints Seasoned Biopharm Exec as New CEO
- Investor Brand Network
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com